La Jolla Pharmaceutical Co. Watch

from SC14D9C 14 pages Support Agreement

from SC TO-C 14 pages Support Agreement

from 8-K 14 pages Support Agreement

from 10-Q ~1 page B. if La Jolla Terminates Your Employment Without Cause, or You Terminate Your Employment for Good Reason Within 12 Months After a Change in Control Event (As Defined in Attachment A), Then: (1) You Will Receive as Severance Pay an Amount Equal to Eighteen (18) Months of Your Then­current Base Salary (Subject to All Applicable Federal, State and Local Tax Withholdings, and Payable Over a Eighteen­month Period in Accordance With La Jolla's Regular Payroll Practices); (2) You Will Receive 100% of Your Then­current Annual Target Bonus (Subject to All Applicable Federal, State and Local Taxes and Withholdings and Payable in a Lump Sum); and (3) La Jolla Will Pay Your Cobra Premiums for Medical, Dental and Vision Insurance for You, Your Spouse and Covered Dependents, Provided That You Are Eligible for and Elect Cobra Coverage, Until the Earlier Of: (I) Eighteen (18) Months After Your Employment Ends; or (II) the Date That You Become Employed by a New Employer. /S/ Kevin Tang Kevin Tang Chairman of the Board Accepted: /S/ Larry Edwards 8/17/21 Larry Edwards Date

from 8-K12B 10 pages La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan

from 8-K12B 10 pages La Jolla Pharmaceutical Company Amended and Restated 2013 Equity Incentive Plan

from 8-K12B 11 pages Indemnification Agreement

from 10-K 18 pages 1.6. Identification of Prime Lease and All Amendments Thereto: Lease Dated June 10, 2011, by and Between Prime Landlord, as Landlord, and Verisk Health Inc., Predecessor to Sublandlord, as Tenant, as Amended By: (I) First Amendment to Lease Dated December 26, 2012, by and Between Prime Landlord and Verisk Health Inc., Predecessor to Sublandlord, and (II) Second Amendment to Lease Dated January 2, 2018, by and Between Prime Landlord and Verscend Technologies, Inc., Predecessor to Sublandlord (Collectively, the “Prime Lease”). a Copy of the Prime Lease Is Attached Hereto as Exhibit C. 1.7. Sublease Term: Two (2) Years, Eleven (11) Months, or Such Shorter Period of Time Between the Commencement Date and Expiration Date, if the Commencement Date Is After January 1, 2021 1.8. Commencement Date: Upon the Latter of (I) Full Execution of This Sublease and Consent Thereto by Prime Landlord, or (II) January 1, 2021 (The “Commencement Date”) 1.9. Expiration Date: November 30, 2023

from 10-K 77 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Confidential License Agreement by and Between Tetraphase Pharmaceuticals, Inc. and Everest Medicines Limited Confidential

from 10-K 84 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omission. Master Manufacturing Services Agreement 14 June 2017

from 10-K 10 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Fourth Amendment to License Agreement

from 10-K 56 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. License Agreement Between Tetraphase Pharmaceuticals, Inc. and President and Fellows of Harvard College

from 10-K 40 pages This Licence Agreement Is Dated as of 12 January 2021 Parties

from 10-Q 5 pages July 27, 2020 Larry Edwards Ledwards@tphase.com 1. Position: You Will Serve as the President and Chief Executive Officer of La Jolla, and You Will Report to La Jolla's Board of Directors (The "Board")

from 8-K 22 pages Contingent Value Rights Agreement

from 8-K 12 pages Form of Exchange Agreement

from SC TO-C 12 pages Form of Exchange Agreement

from 8-K 15 pages Form of Support Agreement

from SC TO-C 15 pages Form of Support Agreement

from 8-K 21 pages Exhibit D Form of Contingent Value Rights Agreement